Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 152.66
EXAS's Cash to Debt is ranked higher than
79% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. EXAS: 152.66 )
EXAS' s 10-Year Cash to Debt Range
Min: 12.24   Max: No Debt
Current: 152.66

F-Score: 4
Z-Score: 89.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1741.95
EXAS's Operating margin (%) is ranked higher than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. EXAS: -1741.95 )
EXAS' s 10-Year Operating margin (%) Range
Min: -51374.51   Max: 1150.29
Current: -1741.95

-51374.51
1150.29
Net-margin (%) -1731.04
EXAS's Net-margin (%) is ranked higher than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. EXAS: -1731.04 )
EXAS' s 10-Year Net-margin (%) Range
Min: -46049.02   Max: 1123.53
Current: -1731.04

-46049.02
1123.53
ROE (%) -36.87
EXAS's ROE (%) is ranked higher than
69% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. EXAS: -36.87 )
EXAS' s 10-Year ROE (%) Range
Min: -505.37   Max: -26.92
Current: -36.87

-505.37
-26.92
ROA (%) -34.43
EXAS's ROA (%) is ranked higher than
67% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. EXAS: -34.43 )
EXAS' s 10-Year ROA (%) Range
Min: -95.07   Max: -18.9
Current: -34.43

-95.07
-18.9
ROC (Joel Greenblatt) (%) -542.57
EXAS's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. EXAS: -542.57 )
EXAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3463.3   Max: -641.7
Current: -542.57

-3463.3
-641.7
Revenue Growth (%) -22.70
EXAS's Revenue Growth (%) is ranked higher than
65% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. EXAS: -22.70 )
EXAS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 47.4
Current: -22.7

0
47.4
EBITDA Growth (%) 33.80
EXAS's EBITDA Growth (%) is ranked higher than
96% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. EXAS: 33.80 )
EXAS' s 10-Year EBITDA Growth (%) Range
Min: -39.4   Max: 45.4
Current: 33.8

-39.4
45.4
EPS Growth (%) 33.50
EXAS's EPS Growth (%) is ranked higher than
94% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. EXAS: 33.50 )
EXAS' s 10-Year EPS Growth (%) Range
Min: -43.1   Max: 46.5
Current: 33.5

-43.1
46.5
» EXAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

EXAS Guru Trades in Q1 2013

Tom Russo 439 sh (New)
RS Investment Management 871,720 sh (+1.85%)
Pioneer Investments Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
» More
Q2 2013

EXAS Guru Trades in Q2 2013

Tom Russo Sold Out
RS Investment Management Sold Out
» More
Q1 2014

EXAS Guru Trades in Q1 2014

George Soros 200,000 sh (New)
Paul Tudor Jones 11,040 sh (New)
» More
Q2 2014

EXAS Guru Trades in Q2 2014

PRIMECAP Management 2,491,300 sh (New)
Chase Coleman 2,000,000 sh (New)
Louis Moore Bacon 100,000 sh (unchged)
George Soros Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 New Buy0.05%$11.17 - $17.27 $ 23.7773%2491300
George Soros 2014-06-30 Sold Out 0.03%$11.17 - $17.27 $ 23.7773%0
George Soros 2014-03-31 New Buy0.03%$11.75 - $14.82 $ 23.7777%200000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - Jun 20, 2014

Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp
Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value. Read more...

Ratios

vs
industry
vs
history
P/B 8.11
EXAS's P/B is ranked higher than
67% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. EXAS: 8.11 )
EXAS' s 10-Year P/B Range
Min: 1.49   Max: 37
Current: 8.11

1.49
37
EV-to-EBIT -29.32
EXAS's EV-to-EBIT is ranked higher than
67% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EXAS: -29.32 )
EXAS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -29.32

Current Ratio 24.32
EXAS's Current Ratio is ranked higher than
97% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. EXAS: 24.32 )
EXAS' s 10-Year Current Ratio Range
Min: 1.02   Max: 50.84
Current: 24.32

1.02
50.84
Quick Ratio 24.32
EXAS's Quick Ratio is ranked higher than
97% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. EXAS: 24.32 )
EXAS' s 10-Year Quick Ratio Range
Min: 1.02   Max: 50.84
Current: 24.32

1.02
50.84

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.86
EXAS's Price/Net Cash is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. EXAS: 8.86 )
EXAS' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 90
Current: 8.86

2.02
90
Price/Net Current Asset Value 8.86
EXAS's Price/Net Current Asset Value is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. EXAS: 8.86 )
EXAS' s 10-Year Price/Net Current Asset Value Range
Min: 2.02   Max: 90
Current: 8.86

2.02
90
Price/Tangible Book 8.11
EXAS's Price/Tangible Book is ranked higher than
73% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. EXAS: 8.11 )
EXAS' s 10-Year Price/Tangible Book Range
Min: 1.88   Max: 34.23
Current: 8.11

1.88
34.23
Forward Rate of Return (Yacktman) 34.42
EXAS's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. EXAS: 34.42 )
EXAS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -168.9   Max: 32.4
Current: 34.42

-168.9
32.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EXK.Germany
Exact Sciences Corporation was incorporated in the State of Delaware on February 10, 1995. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85 percent at a specificity of 90 percent. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon. When colorectal cancer or pre-cancer is present, a minute portion of the total isolated human DNA will often represent DNA shed from cancerous or pre-cancerous lesions. Once the human DNA in the sample is isolated, sDNA detection looks for specific mutations and other abnormalities in that DNA known to be associated with colorectal cancer. Its test also detects blood in stool, utilizing an antibody-based FIT test. Certain of the Company's activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products.
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Tal Oct 15 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 
cooldecency99 note on EXAS May 01 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 

More From Our Partners
CNBC's Stock Pops & Drops From October 10 Oct 12 2014 - BENZINGA

More From Other Websites
Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Oct 20 2014
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business... Oct 15 2014
Can the Rally in EXACT Sciences (EXAS) Shares Continue? Oct 15 2014
UPDATE: Wedbush Reiterates On EXACT Sciences Corporation Following Favorable CMS Coverage And... Oct 13 2014
Exact Sciences (EXAS) Looks Strong: Stock Surges 35.8% Oct 13 2014
Exact Sciences up on test Oct 10 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 10 2014
[video] Stock Pops & Drops: EXAS, JCP, BUD & PLAY Oct 10 2014
Exact Sciences soars on colon cancer test ruling Oct 10 2014
Exact Sciences soars on colon cancer test ruling Oct 10 2014
Tech, Semiconductors Among Worst Performers As Sell-Off Continues Oct 10 2014
The week ended like it started, in volatile fashion Oct 10 2014
Cramer: Exact Science Soars on Medicare Coverage Announcement Oct 10 2014
Microchip Technology Dips On Sales Warning Oct 10 2014
[$$] Exact Sciences Gets Boost From Medicare Proposal Oct 10 2014
Exact Sciences Soars As Test Gets National Coverage Oct 10 2014
[video] Cramer's Mad Dash: Exact surges Oct 10 2014
Medicare Recommends $500 Reimbursement for Exact Sciences' Colon Cancer Test Oct 10 2014
Exact Sciences Announces Final National Coverage Determination for Cologuard® Oct 09 2014
Exact Sciences Colon Cancer Test Awaits The Money Man Oct 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK